MEDX Oncology East


Session 3: Navigating New Options to Improve Outcomes in Multiple Myeloma

Thursday, September 7     11:30am – 12:30pm

Description

As new combinations and classes of agents emerge for the treatment of multiple myeloma (MM), community-based treatment teams require clarity on the optimal integration of recently approved and emerging agents into the relapsed/refractory landscape for MM. While high-dose chemotherapy is not appropriate for all patients, multiple options have emerged that demonstrate a clinical benefit and require proper integration into the treatment paradigm. In addition, clinicians must meet requirements for reimbursement and demonstrate evidence-based, guideline-adherent, quality care with justification for selection and accurate documentation.

Session Outline

Faculty will discuss 2-3 patient stories to highlight the factors that impact treatment decisions in multiple myeloma. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Safety, efficacy, and response monitoring
  • Risk-adapted treatment strategies: early relapsed vs heavily pretreated patients
  • Novel classes of agents and emerging clinical trial data
  • Considerations for the infusion team

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon